Discovery
The Gila monster is a venomous lizard of the US Southwest and northern Mexico. In the early 1990s, John Eng, an endocrinologist at the Veterans Affairs Medical Center in the Bronx, New York, was screening lizard venoms for new hormones. In 1992 he reported a 39-amino-acid peptide from Gila monster venom that he named exendin-4.
The Gila monster (Heloderma suspectum) is a large, slow-moving lizard that can go months between meals. It is one of very few venomous lizards. Exendin-4 shares about half of its amino acid sequence with human GLP-1, which is enough to switch on the same receptor.
Exendin-4 turned out to act on the same receptor as human GLP-1, a gut hormone that raises insulin after meals. Human GLP-1 breaks down in minutes, but exendin-4 resists the enzyme that destroys it and lasts for hours. That made it a candidate for a diabetes drug.
Development of Byetta
The small company Amylin Pharmaceuticals licensed exendin-4 and made a synthetic version called exenatide, later developing it with Eli Lilly. The FDA approved it as Byetta, a twice-daily injection for type 2 diabetes, on April 28, 2005. It was the first GLP-1 receptor agonist on the market.
Bydureon and later years
A slow-release form, Bydureon, was approved on January 27, 2012. It packed exenatide into tiny microspheres that release the drug over a week, making it the first once-weekly diabetes treatment. AstraZeneca later took over the products and launched the Bydureon BCise autoinjector in 2017. The weekly forms carried a boxed warning about thyroid C-cell tumors seen in rats, a warning later shared by other weekly GLP-1 medicines.
In November 2024, the FDA approved the first generic exenatide referencing Byetta, the first generic in the GLP-1 class. Around the same time, AstraZeneca stopped selling Byetta and Bydureon BCise in the US. Newer weekly drugs such as semaglutide and tirzepatide had taken most of the market.
Legacy
Exenatide showed that a GLP-1 drug could lower blood sugar and that people taking it often lost weight. Later medicines such as liraglutide were built on human GLP-1 rather than lizard venom, but the class traces back to the Gila monster. Today's options are compared on our medication comparison page.
Timeline
- 1992-04-15John Eng publishes the isolation of exendin-4 in the Journal of Biological Chemistry
- 2005-04-28Byetta, twice-daily exenatide, approved for type 2 diabetes
- 2012-01-27Bydureon, the first once-weekly diabetes treatment, approved
- 2017-10-20Bydureon BCise autoinjector approved
- 2024-10Byetta and Bydureon BCise discontinued in the US by AstraZeneca
- 2024-11First generic referencing Byetta approved
See also
References
- Eng et al., J Biol Chem 1992;267:7402-5 (exendin-4). pubmed.ncbi.nlm.nih.gov
- Bydureon approval package, NDA 022200, FDA (January 27, 2012). accessdata.fda.gov
- FDA approves first generic of once-daily GLP-1 injection (FDA, December 23, 2024; notes the generic Byetta approval). fda.gov
- UnitedHealthcare provider notice: discontinuation of Bydureon BCise and Byetta (December 2024)
Last updated . Category: History & timeline. Browse all 38 WikiTelehealth entries.